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Background:  Catheter ablation of isthmus-dependent atrial flutter has emerged as a durable treatment of atrial flutter. It is common to utilize 
transesophageal echocardiography (TEE) prior to ablation of atrial flutter in patients with subtherapeutic antiocoagualtion or atrial flutter duration 
of longer than 48 hours to rule out left atrial thrombus (LAT). This practice is an extrapolation of guidelines regarding atrial fibrillation (afib) 
and little is known of the prevalence of LAT in patients presenting for atrial flutter ablation. It would be of use to report the prevalence of LAT in 
patients presenting for ablation of atrial flutter as a validation of current practice standards. It would also be useful to understand the clinical and 
echocardiographic parameters associated with thrombogenesis in these patients. This would allow for more judicious usage of TEE thus improving 
patient safety and resource allocation.
Methods:  From 11/19/08 to 6/30/2010, 348 consecutive patients underwent TEE prior to atrial flutter ablation. The indications for TEE were 
previous subtherapeutic anticoagulation or new onset atrial flutter duration of > 48 hrs. All underwent TEE within four days of planned ablation. 
TEE’s were performed by experienced echocardiographers. Clinical data including laboratory parameters, comorbidities, and echocardiographic 
parameters were recorded in a database.
Results:  Of presenting patients, 5.5% (19 of 348) were found to have LAT. Of these patients, 42.1% had comorbid afib. This rate was comparable 
to patients without LAT, where there was 55.7% rate of comorbid afib. Clinical conditions associated with LAT were diabetes (57.9% vs. 36.0% p = 
0.055) and prior myocardial infarction (MI) (36.8% vs. 14.8% p = 0.02). No two dimensional echocardiographic data were associated with LAT. TEE 
parameters associated with LAT were spontaneous echo contrast (47.1% vs. 13.1% p < 0.0001) and reduced left atrial appendage emptying velocity 
(27.7 vs 49.4 cm/s, p <0.001).
Conclusions:  LAT is a relatively rare but not uncommon finding in patients presenting for atrial flutter ablation. TEE is especially indicated if 
patients posses comorbid coronary artery disease with previous MI, and diabetes.
